



NANETS

NORTH AMERICAN NEUROENDOCRINE TUMOR SOCIETY

ABSTRACT POSTER GUIDE

2026 MULTIDISCIPLINARY NET MEDICAL SYMPOSIUM







BASIC SCIENCE

Number	Title	Presenting Author
B-2	Identification of a recurrent fusion oncogene as a potential therapeutic target in pancreatic neuroendocrine tumors	Daniel DePietro, MD
B-3	Epigenetic MTAP Loss Expands the Therapeutic Window of PRMT5 Inhibition in Gastroenteropancreatic Neuroendocrine Tumors	Danping Niu, PhD
B-4	Validation of PAM expression in PNETs using Targeted Spatial Proteomics	Faris Zaibaq, BS
B-5	Development of patients-derived NET organoids	Francisca Beato
B-10	Tumor Microenvironment Remodeling Mediates Resistance to 177Lu-DOTATATE in Metastatic Well-Differentiated Neuroendocrine Tumors	Rahil Abbu, MS, CCRP
B-11	Loss of nuclear Menin alters lipid homeostasis in pancreatic neuroendocrine tumor cells	Suzann Duan, PhD
B-13	Cardiac Arrhythmogenic Sensitivity in a Rat Model of Neuroendocrine Tumor Metastasis	Yasmin Saber-Tehrani, BS

APPLIED BASIC SCIENCE

Number	Title	Presenting Author
B-1	Expression patterns of novel genomic markers in pulmonary versus extra-pulmonary small cell neuroend	Amr Mohamed, MD
B-6	Integrated Bulk and Single-Cell Transcriptomics Identify Liver-Adaptive Tumor States in Metastatic siNET	James Madigan, PhD
B-7	Initial Cellular Characterization and Therapeutic Targeting of the Alternative Lengthening of Telomeres Phenotype in PNETs: Role of Telomeric Replication Stress	James Madigan, PhD
B-9	Unmasking High-Grade (HG) Neuroendocrine Carcinoma (NEC) biology through transcriptomic profiling in lung and bladder cancer	Parth Desai, MD
B-12	Allosteric ClpP agonist JZP3507 (formerly ONC206) alters mitochondrial metabolism, stress response and chromatin accessibility to elicit apoptosis in pheochromocytoma	Varun Prabhu, PhD
B-14	BH3-mimetics synergise with systemic therapies to induce apoptosis in patient-derived neuroendocrine tumour organoids	Zoey Wang, M.Phil., BA
B-15	Tumor microenvironment features in extrapulmonary neuroendocrine carcinomas for predicting response to immunotherapy and platinum-based therapy	Joseph Kim, M.D, PhD

CHEMO/SSA/BIOLOGICS (CLINICAL)

Number	Title	Presenting Author
C-1	Efficacy and Safety of Cabozantinib in Advanced Neuroendocrine Tumors By Hormone Functional Status: Subgroup Analysis of Phase 3 CABINET Trial	Nikolaos Trikalinos, MD
C-2	Cabozantinib in high grade neuroendocrine neoplasms.	Nikolaos Trikalinos, MD
C-7	Characterizing Long-Term Hematologic Toxicity After ^{177}Lu-DOTATATE: A Real-World Analysis of Patients with Gastrointestinal Neuroendocrine Tumors	Apurwa Prasad, MD
C-12	Clinical Outcomes and Toxicity Profile of Cabozantinib in Advanced Neuroendocrine Tumors: A Multi-Center Real World Analysis	Charles Shi, MD
C-13	Phase I Study of Fulvestrant in Combination with 177Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors	Chih-Yi Liao, MD
C-15	Therapy-Related Myeloid Neoplasms After Radioligand Therapy in Neuroendocrine Tumors: A Multicenter Real-World Analysis	Deevyashali Parekh, MBBS
C-21	A Phase I Study of Safety, Immunogenicity, and Preliminary Clinical Activity of the Survivin Long Peptide Vaccine (SurVaxM) in Patients with Metastatic Neuroendocrine Neoplasm	Jasmeet Kaur, MD, FACP

CHEMO/SSA/BIOLOGICS (CLINICAL)

Number	Title	Presenting Author
C-26	NETest2.0® Accurately Detects Active Disease and Monitors Recurrence in Neuroendocrine Tumors: Results from the RegisterNET Registry	Mark Kidd, PhD
C-27	Beyond Chromogranin A: Molecular Surveillance with NETest2.0® Improves Detection of Neuroendocrine Tumor Progression	Mark Kidd, PhD
C-28	Longer-Term Paltusotine Treatment in Patients With Carcinoid Syndrome: Safety and Exploratory Efficacy Results From a 2-Year Open-Label Extension Study	Mary Maluccio, MD, MPH
C-29	Laser Capture Microdissection-Based Proteomics to Identify Immunotherapy Response Signatures in High-Grade Neuroendocrine Neoplasms	Patrick McGarrah, MD
C-30	Real World Analysis of Extrapulmonary Neuroendocrine Carcinoma Patients in South Florida.	Rakhi Modak, MS
C-35	Brain Metastases in Patients with Pulmonary Neuroendocrine Tumors: Clinical Characteristics, Risk Factors, and Outcomes	Skylar Robbins
C-40	Outcomes with first-line obrixtamig plus standard of care in epNEC by DLL3 expression status: Phase Ib DAREON®-7 study	Aman Chauhan, MD
C-41	A Phase 1 Trial of the Oncolytic Virus SVV-001 with Nivolumab and Ipilimumab in Patients with High Grade Neuroendocrine Neoplasms.	Aman Chauhan, MD
C-42	First-Line Systemic Therapy Patterns and Survival in Advanced Neuroendocrine Carcinoma: An Agent-Level Registry Analysis	Sanjay Shankar, BS
C-44	Phase 1b Study of Zocilurtatug Pelitecan in Patients with Advanced Extra-Pulmonary Neuroendocrine Carcinomas	Amr Mohamed, MD

NUCLEAR MEDICINE/INTERVENTIONAL RADIOLOGY/IMAGING (CLINICAL)

Number	Title	Presenting Author
C-4	DOTATATE PET/CT at Diagnosis Is Associated With Decreased Mortality in Gastroenteropancreatic Well-Differentiated Neuroendocrine Tumors: A Propensity-Matched Retrospective Cohort Study	Ahmed Al-Shammari, BS
C-5	Bowel Obstruction in Patients with Neuroendocrine Tumor (NET) Treated With ^{177}Lu-DOTATATE: A Comparative Cohort and Time-to-Event Analysis	Alvaro Ordonez, MD
C-6	Hematologic Effects of Splenectomy in Patients with Pancreatic Neuroendocrine Tumors who Receive ^{177}Lu-DOTATATE PRRT	Alvaro Ordonez, MD
C-11	Normal Organ Dosimetry to Guide Safe Re-treatment PRRT	Eric Mitra, MD, PhD
C-14	Retreatment With 177Lu-DOTATATE in Well-Differentiated Neuroendocrine Tumors: Interim Analysis of a Multicenter Registry	Courtney Porfido, BA
C-16	Diagnostic performance of 64Cu-SARTATE compared to 68Ga-DOTATATE in patients with known or suspected neuroendocrine tumors with focus on liver findings	Erica Sztangret, PharmD
C-18	[177Lu]Lu-edotreotide Effectiveness in Patients with Functional and Non-functional Gastrointestinal Neuroendocrine Tumors: A SwissNET Registry Analysis	William Yoon, PharmD
C-20	Outcomes of TARE as salvage liver-directed therapy in patients with poor response to first-line TAE/TACE for neuroendocrine liver metastases	Jamal Magoti, BS
C-23	A Retrospective Review of Patient's Octreotide Administration During 177Lu-Dotatate Treatment	Kimberly Freitas, DNP
C-37	Real-World Utilization of Circulating Biomarkers in Well-Differentiated Gastroenteropancreatic Neuroendocrine Neoplasms	Ahmed Al- Shammari, MS
C-39	Real-World Evidence of Response to 177Lu-DOTATATE PRRT Based on Primary and Metastatic Sites in Patients with Neuroendocrine Tumor	Yash Shah, MD

SURGERY/APPLIED PATHOLOGY (CLINICAL)

Number	Title	Presenting Author
C-3	Stage-Independent Prognostic Value of TP53 and DAXX/ATRX in Pancreatic Malignant Carcinoid and Neuroendocrine Carcinoma	Aasiya Islam, BS
C-8	Patterns of Metastases and Outcomes in Patients with Pancreatic Neuroendocrine Tumors	Brandon Toliver, MD
C-9	Emergency versus elective resection for small intestine neuroendocrine tumors: a population-based analysis of short-term post-operative outcomes.	Carlotta Sarzo, MD
C-10	Patient-reported symptom burden after surgery for entero-pancreatic neuroendocrine tumors: a population-level analysis.	Carlotta Sarzo, MD
C-19	Toward a Ki-67 -Informed Grading Framework for Metastatic Pulmonary Neuroendocrine Tumors	Hayden Stoltzfoos, BA
C-22	Preoperative Somatostatin Receptor-based Imaging Should be Routinely Performed in Neuroendocrine Tumors	Jeremy Chang, MS, MD
C-24	Time-Dependent Recurrence Risk and Prognostic Factors After Hepatic Resection for Neuroendocrine Liver Metastases	Kyoji Ito, MD, PhD
C-25	Building an international research agenda for the surgical care of gastro-entero-pancreatic neuroendocrine tumors: results of the CUTNETs modified Delphi consensus phase.	Lev Bubis, MD, FRCSC
C-31	Recurrence of Locoregional Small Bowel Neuroendocrine Tumors: Developing a Risk Prediction Nomogram	Richa Bisht, MD
C-32	Timing of Primary Tumor Resection & Long-Term Survival in Stage IV Small Bowel Neuroendocrine Tumors: A National Analysis	Roberto Alva-Ruiz, MD
C-33	Prognostic Significance of Ki-67 Proliferation Index in Pulmonary Carcinoid Tumors: A Single-Center Retrospective Cohort Study	Rylan Howell, MD
C-34	Improvements in long-term survival for neuroendocrine neoplasm patients (2000-2025) reflecting over 2000 cytoreductive surgeries	Sarah Jacques, MD
C-36	Grade Progression and Morphologic Transformation in Neuroendocrine Tumors: A Single-Institution Retrospective Analysis	Sonal Gandhi, MD
C-38	Clinical Impact of Endoscopic Ultrasound Tissue Acquisition on Pancreatic Lesions ≤10mm	Yara Salameh, MD
C-43	Survival after resection of entero-pancreatic neuroendocrine tumors: a population-based analysis.	Julie Hallet, MD, MSc, FRCSC, FSSO

POPULATION SCIENCE

Number	Title	Presenting Author
P-1	Liver Metastases Independently Predict Worse Overall Survival in Neuroendocrine Carcinoma: A Differentiation-Stratified Analysis	Sanjay Shankar, BS
P-2	Directional Misclassification of WHO Neuroendocrine Differentiation in a CoC Registry: Implications for SEER and NCDB Outcomes Research	Sanjay Shankar, BS
P-3	Two decades of advances in neuroendocrine neoplasms care: has survival changed over time?	Julie Hallet, MD, MSc, FRCSC, FSSO
P-4	Time to Treatment Initiation (TTI) and Survival Outcomes in Metastatic Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)	Abdullah Alsulaiman, MD
P-5	Functional Neuroendocrine Neoplasms (NENs) With Parathyroid Hormone–Related Peptide (PTHrP)-Mediated Hypercalcemia: A Retrospective Study	Abdullah Alsulaiman, MD
P-6	Meeting exercise guidelines is associated with improved quality of life in patients with advanced neuroendocrine neoplasms: Results from NET Voices	Alan Paciorek, BS

POPULATION SCIENCE

Number	Title	Presenting Author
P-7	Characterization of Gastroenteropancreatic Neuroendocrine Neoplasms in Older Adults	Amy Zeng, BA
P-8	WHO Mitotic/Ki-67 Grading Completeness and Distribution in Neuroendocrine Neoplasms (NENs), in the Surveillance, Epidemiology, and End Results (SEER) Program	Arvind Dasari, MD
P-10	Characterizing the Epidemiology and Treatment Patterns of Carcinoid Syndrome Among Neuroendocrine Neoplasms in a Large Population-Based Database	Heloisa Soares, MD, PhD
P-11	NANETS NETPact Survey on Barriers to Providing Care for Neuroendocrine Cancer: A Dual-Perspective Analysis of Patient and Provider Experiences	Heloisa Soares, MD, PhD
P-12	Clinical Profile of Brain Metastases in Lung and High-Grade Neuroendocrine Neoplasms	Joseph Watts, BS
P-13	Prognostic Associations of Metastatic Site at Diagnosis in Neuroendocrine Neoplasms	Joseph Watts, BS
P-14	Composite Metastatic Organ Burden Refines Prognostic Stratification Beyond AJCC M1 Substaging in Neuroendocrine Neoplasms	Joseph Watts, BS
P-15	Germline pathogenic/likely pathogenic (P/LP) variants in epithelial neuroendocrine neoplasms: The case for universal germline genetic testing	Matthew Gao, BS
P-16	Patient-Reported Outcomes and Demographic Representation in Contemporary Phase III/IV Neuroendocrine Tumor Clinical Trials: A Systematic Trial-Level Review	Nitya Batra, MD
P-17	Overall Survival and Prognostic Factors in Patients with Gastroenteropancreatic Neuroendocrine Carcinoma: A Large Population-Based Analysis	Rishi Patel, BA
P-18	Treatment Comparisons in the Management of MEN1-Related and Sporadic Pancreatic Neuroendocrine Neoplasms: A Retrospective Study	Tori King, MS
P-19	The Impact of Physical Activity on Fatigue and Quality of Life in Patients with Neuroendocrine Tumors: A Cross-Sectional Study	Victoria Fujimoto, MD

OTHER


Number	Title	Presenting Author
O-1	Long-Term Oncologic Outcomes After Liver Transplantation for Neuroendocrine Liver Metastases: A Multisite Mayo Clinic Study	Joseph Kim, MD, PhD
O-2	Real-World Patient Journey in Extrapulmonary Neuroendocrine Carcinoma (epNEC): Perspectives of Patients from the VOICE Study	Aman Chauhan, MD
O-3	Multidisciplinary Clinic for Gastrointestinal Neuroendocrine Tumors: Impact on Diagnosis and Management	Ana De Jesus-Acosta, MD
O-4	Analysis of DLL3 expression levels and characteristics of patients with advanced extrapulmonary neuroendocrine carcinomas from an ongoing phase I trial	Andrea Standring, PharmD
O-5	Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms (PanNENs): Interim Analysis of a Multicenter University of California Cohort	Bryan Khuong Le, BAs
O-6	Building the Future Neuroendocrine Oncology Workforce: Education, Multidisciplinary Collaboration, and Fellowship Development-Proceedings from the 2026 Healing NET Foundation Summit	Eric Liu, MD
O-7	Circulating tumor DNA (ctDNA) monitoring for minimal residual disease (MRD) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs)	Harrison Winters, MD
O-8	Evaluation of Large Language Model-Based Extraction of Neuroendocrine Neoplasm Variables from Pathology Reports	Jasmin Francisco, MS
O-9	Real-World Management of Extrapulmonary Neuroendocrine Carcinoma (epNEC) from the Perspective of Healthcare Providers in the VOICE Study	Jason Starr, DO
O-10	Care Partner Experiences and Burden in Extrapulmonary Neuroendocrine Carcinoma: Findings from the VOICE Survey	Jason Starr, DO

OTHER

Number	Title	Presenting Author
O-11	Empirically informed conceptual framework for shared decision-making for neuroendocrine tumors care: a multicentre international qualitative study.	Julie Hallet, MD, MSc, FRCSC, FSSO
O-12	Assessment of AI-assisted Clinical Trial Matching for Neuroendocrine Neoplasms	Kenneth Chen, MD, PhD
O-13	Clinicopathologic Characteristics and Outcomes of MEN1-Associated Bronchopulmonary Neuroendocrine Neoplasms Carcinoid Tumors: The Mayo Clinic Experience	Lauren Pomerantz, MD
O-14	Clinical Characteristics and Outcomes of MEN1-Associated Thymic Neuroendocrine Tumors Across Mayo Clinic Sites	Lauren Pomerantz, MD
O-15	Neuroendocrine Tumors and Risk of Subsequent Primary Cancers in Early-Onset Disease: A Population-Based Retrospective Cohort Study in the United States	Manas Pustake, MD
O-16	Establishing content validity of patient-reported outcome (PRO) measures in extrapulmonary neuroendocrine carcinomas (epNEC): A cognitive debriefing (CD) interview study	Marianne Pavel, MD
O-17	The Role of NET Specialists in Diagnostics and Treatment – Comparison Global vs USA in 2019 – 2025	Meredith Cummins, RN
O-18	Prognostic significance of B7H3, DLL3, and survivin expression in neuroendocrine neoplasms	Reem Dergham, MD
O-19	Real World Trends in Telotristat Utilization for Carcinoid Syndrome in the United States: A National Epic Cosmos Analysis	Sawsan El Sweilmein, MD
O-20	Histotripsy for Neuroendocrine Tumors Liver Metastases: Safety and Clinical Outcomes in a Single-Institution Series	Sawyer Bawek, DO
O-21	Clinical Utility and Impact of the Healing NET Foundation Virtual Multidisciplinary Tumor Board in the Care of Patients with Neuroendocrine Neoplasms	Udhayvir Grewal, MD
O-22	Drivers and Barriers to Workforce Development in Neuroendocrine Neoplasms: Insights from the NANETS “Why NENs” Early-Career Survey	Udhayvir Grewal, MD
O-23	Structured Chart Abstraction Improves Progression Ascertainment in a Neuroendocrine Neoplasm Registry: A Quality Improvement Initiative	Sanjay Shankar, BS

TRIALS IN PROGRESS


Number	Title	Presenting Author
T-1	Alliance A092204: Phase II Study of Cabozantinib in Combination with Cemiplimab versus Cabozantinib in Adolescents and Adults with Adrenocortical Cancer	Bhavana Konda, MD, MPH
T-2	Hepatic artery infusion therapy for gastro-entero-pancreatic neuroendocrine tumor liver metastases: a patient-derived preclinical study.	Colin Court, MD, PhD
T-4	Trial-in-Progress: A Phase 2 Study of ONC206 (JZP3507) in Patients With Advanced Pheochromocytoma and Paraganglioma	Samuel Ramage, PhD
T-5	Cohort-level safety and efficacy results for [212Pb]VMT-a-NET in advanced somatostatin receptor subtype 2-expressing neuroendocrine tumors: Cohorts 1–3	Thorvardur Halfdanarson, MD
T-6	DAREON®-NEC-1: Phase III trial of first-line obrixtamig plus carboplatin and etoposide (SoC) vs SoC in patients with DLL3-positive epNEC	Thorvardur Halfdanarson, MD
T-7	Zanzalintinib Maintenance in Patients with High Grade Neuroendocrine Neoplasms (HG-NENs)	Nikolaos Trikalinos, MD


NANETS SYMPOSIUM POSTER HALL MAP







VALENCIA BALLROOM

JW MARRIOTT LAS VEGAS RESORT & SPA

NANETS

NORTH AMERICAN NEUROENDOCRINE TUMOR SOCIETY